# EDGAR Filing Document

**Accession Number:** 0001835597
**File Stem:** 0000950170-25-082707
**Filing Date:** 2025-6
**Character Count:** 6056
**Document Hash:** 8d4648a0e33bc9f862931bd85370044e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-082707.hdr.sgml**: 20250606

**ACCESSION NUMBER**: 0000950170-25-082707

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20250606

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250606

**DATE AS OF CHANGE**: 20250606

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PepGen Inc.
- **CENTRAL INDEX KEY:** 0001835597
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41374
- **FILM NUMBER:** 251028959

**BUSINESS ADDRESS:**
- **STREET 1:** 1 MARINA PARK DRIVE, SUITE 900
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210
- **BUSINESS PHONE:** 703-456-8000

**MAIL ADDRESS:**
- **STREET 1:** 1 MARINA PARK DRIVE, SUITE 900
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02210

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## **FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 06, 2025 **(June 04, 2025)**<br>

------

PepGen Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-41374 | 85-3819886 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 321 Harrison Avenue<br>8th Floor |  |  |
| Boston**,** Massachusetts |  | 02118 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (781) 797-0979<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common stock, par value $0.0001 per share | PEPG | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

------

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## **Item 5.07 Submission of Matters to a Vote of Security Holders.** 
The 2025 Annual Meeting of Stockholders (the "2025 Annual Meeting") of PepGen Inc. (the "Company") was held on June 4, 2025. The proposals set forth below were submitted to the stockholders at the 2025 Annual Meeting, with each such proposal described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 25, 2025 in connection with the 2025 Annual Meeting.

The number of shares of common stock entitled to vote at the 2025 Annual Meeting was 32,720,943. The number of shares of common stock present or represented by valid proxy at the 2025 Annual Meeting was 29,425,676. Therefore, a quorum was present. The number of votes cast for and withheld/against and the number of abstentions and broker non-votes with respect to each proposal voted upon are set forth below.

***Proposal 1 - Election of Directors*** 

The Company's stockholders elected the three Class III directors to the Company's board of directors, to serve until the 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Director Nominee** | &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Withheld** |
| &nbsp;&nbsp;Mitchell H. Finer, Ph.D. | &nbsp;&nbsp;27224040 | &nbsp;&nbsp;119403 |
| &nbsp;&nbsp;Heidi Henson | &nbsp;&nbsp;27219131 | &nbsp;&nbsp;124312 |
| &nbsp;&nbsp;Laurie B. Keating, J.D. | &nbsp;&nbsp;22160152 | &nbsp;&nbsp;5183291 |

---

There were 2,082,233 broker non-votes regarding the election of each of Mitchell H. Finer, Heidi Henson and Laurie B. Keating.

***Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm*** 

The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Against** | &nbsp;&nbsp;**Abstentions** |
| &nbsp;&nbsp;29,423,817 | &nbsp;&nbsp;1,821 | &nbsp;&nbsp;38 |

---

There were zero broker non-votes regarding this proposal.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **PEPGEN INC.** |
| Date: | June 6, 2025 | By:  | /s/ Noel Donnelly |
|  |  |  | Noel Donnelly, Chief Financial Officer |

---

------